| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Microtubule/tubulin in parasitic cells. R-18986, as the amine metabolite of mebendazole, is expected to interact with tubulin, the protein that forms microtubules essential for the cell's cytoskeleton. By targeting tubulin, the compound disrupts microtubule dynamics, leading to impaired cellular functions in susceptible organisms.
|
|---|---|
| ln Vitro |
In vitro activity of R-18986 is primarily studied in the context of its parent compound mebendazole. As a metabolite, it may retain some degree of anti-tubulin activity, though its potency is generally lower than that of the parent drug. The compound is used as a standard in analytical methods to quantify mebendazole metabolism and to assess metabolite formation in hepatic microsomal preparations. Its biochemical activity serves as a reference for understanding the metabolic fate of mebendazole.
|
| ln Vivo |
In vivo, R-18986 is produced as a major metabolite following administration of mebendazole. Its systemic exposure contributes to the overall pharmacokinetic profile of the parent drug. The metabolite is primarily formed in the liver and is excreted via renal and biliary routes. Its presence in plasma and tissues is monitored in pharmacokinetic studies to evaluate the metabolic clearance and bioavailability of mebendazole formulations.
|
| Enzyme Assay |
Cell-free enzyme assays for R-18986 typically involve incubation of the compound with liver microsomes or recombinant cytochrome P450 enzymes to study its formation and further metabolism. The compound is used as a reference standard in HPLC or LC-MS/MS methods for quantifying mebendazole and its metabolites. Binding studies to tubulin can be performed using purified tubulin protein and measuring the inhibition of tubulin polymerization spectrophotometrically at 340 nm, with IC50 values calculated from dose-response curves.
|
| Cell Assay |
In vitro cell-based assays for R-18986 are limited as it is primarily a metabolite standard. When used in cellular systems, it may be tested for anti-proliferative activity against parasitic cell lines or mammalian cancer cell lines to assess residual activity. Cells are seeded in multiwell plates, treated with varying concentrations of R-18986 for 24-72 hours, and cell viability is measured using MTT or CCK-8 assays. IC50 values are determined from dose-response curves to compare activity with the parent compound mebendazole.
|
| Animal Protocol |
In vivo animal studies involving R-18986 are typically pharmacokinetic studies where the compound is administered to rodents (e.g., rats or mice) via oral or intravenous routes. Blood samples are collected at various time points post-administration, and plasma concentrations of R-18986 are measured by LC-MS/MS. Tissue distribution studies may also be performed to assess organ-specific accumulation. The compound serves as a key analyte in studies evaluating the metabolic profile and disposition of mebendazole in preclinical species.
|
| ADME/Pharmacokinetics |
As a metabolite of mebendazole, R-18986 is formed via hepatic metabolism and circulates in the systemic circulation. Its pharmacokinetic parameters (half-life, clearance, volume of distribution) are dependent on the parent drug's disposition. The compound is primarily eliminated through renal excretion and biliary elimination. Its plasma protein binding and tissue distribution are assumed to be similar to other benzimidazole metabolites. Detailed PK data are typically generated alongside parent drug pharmacokinetic studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for R-18986 are not extensively reported, as it is a metabolite and not a therapeutic agent itself. The safety profile is expected to be related to that of mebendazole, which is clinically used as an anthelmintic with a well-established safety margin. At research-grade concentrations, the compound is handled with standard laboratory precautions. No specific toxicological findings have been attributed to this metabolite in published literature.
|
| References | |
| Additional Infomation |
2-Amino-5-benzoylbenzimidazole is a member of the benzophenone class of compounds.
R-18986 is a biochemical reference standard used primarily in analytical chemistry and pharmacokinetic research. It is not a therapeutic agent and has not been evaluated in clinical trials. The compound is available from chemical suppliers for research purposes only. It is typically stored at -20°C and handled according to standard laboratory safety protocols. Its role as a metabolite standard makes it valuable for drug metabolism and pharmacokinetics (DMPK) studies. |
| Molecular Formula |
C14H11N3O
|
|---|---|
| Molecular Weight |
237.26
|
| Exact Mass |
237.09
|
| CAS # |
52329-60-9
|
| Related CAS # |
Mebendazole-amine-13C6
|
| PubChem CID |
40320
|
| Appearance |
White to off-white solid powder
|
| Density |
1.351g/cm3
|
| Boiling Point |
504.5ºC at 760 mmHg
|
| Melting Point |
176-185°C
|
| Flash Point |
258.9ºC
|
| Index of Refraction |
1.738
|
| LogP |
2.306
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
314
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)C(=O)C2=CC3=C(C=C2)NC(=N)N3
|
| InChi Key |
GPMHHSJZGVOEFS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H11N3O/c15-14-16-11-7-6-10(8-12(11)17-14)13(18)9-4-2-1-3-5-9/h1-8H,(H3,15,16,17)
|
| Chemical Name |
(2-amino-3H-benzimidazol-5-yl)-phenylmethanone
|
| Synonyms |
R18986; R 18986; R-18986
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2148 mL | 21.0739 mL | 42.1479 mL | |
| 5 mM | 0.8430 mL | 4.2148 mL | 8.4296 mL | |
| 10 mM | 0.4215 mL | 2.1074 mL | 4.2148 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
